Advertisement
New Zealand markets close in 2 hours 18 minutes
  • NZX 50

    11,793.14
    -82.21 (-0.69%)
     
  • NZD/USD

    0.5928
    +0.0009 (+0.15%)
     
  • NZD/EUR

    0.5550
    +0.0008 (+0.15%)
     
  • ALL ORDS

    7,900.70
    +39.70 (+0.51%)
     
  • ASX 200

    7,644.50
    +38.90 (+0.51%)
     
  • OIL

    82.81
    +0.12 (+0.15%)
     
  • GOLD

    2,385.90
    -2.50 (-0.10%)
     
  • NASDAQ

    17,493.62
    -220.04 (-1.24%)
     
  • FTSE

    7,847.99
    +27.63 (+0.35%)
     
  • Dow Jones

    37,753.31
    -45.66 (-0.12%)
     
  • DAX

    17,770.02
    +3.79 (+0.02%)
     
  • Hang Seng

    16,398.81
    +146.97 (+0.90%)
     
  • NIKKEI 225

    38,041.88
    +80.08 (+0.21%)
     
  • NZD/JPY

    91.3000
    +0.0120 (+0.01%)
     

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.